The association between pCR and enhanced disease-free survival (DFS) and overall survival (OS) is well known, particularly in aggressive breast cancer subtypes such as triple-negative and HER2-positive breast cancers [5–7]. This evidence concerns the gene ERBB2 and breast carcinoma.